XML 33 R22.htm IDEA: XBRL DOCUMENT v3.26.3
Note 16 - Asset Acquisitions
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Asset Acquisition [Text Block]

Note 16. Asset Acquisitions

 

On January 24, 2025, the Company acquired 100% of the membership interests of Perikard, LLC, which was accounted for as an asset acquisition consisting primarily of a single patent for pericardial access technology. The Company issued 1,447 shares of its common stock valued at $113 thousand as consideration and is obligated to make royalty payments equal to 10% of net sales of the pericardial access kit for five years following the closing date. The patent was determined to be IPR&D with no alternative future use, and accordingly, the Company recognized $119 thousand, consisting of $113 thousand of stock consideration and $6 thousand of direct transaction costs for the nine months ended September 30, 2025. The Perikard membership interests were transferred to Mr. Jenkins on December 31, 2025 (see Note 9, Notes Payable). 

 

On May 5, 2025, Cardionomix acquired certain assets from Cardionomic. The assets primarily related to Cardionomic’s CPNS System, which represents a novel technology for the late-stage treatment of acute decompensated heart failure. 

 

The acquisition was accounted for as an asset acquisition consisting primarily of an IPR&D Asset (the CPNS System). The Company issued 5,263 shares of its restricted common stock valued at $0.3 million, and Cardionomix issued a promissory note recorded at a carrying amount of $1.3 million (the "Note Payable"), as consideration to Cardionomic. The IPR&D Asset was determined to have no alternative future use, and accordingly, the Company expensed the costs of acquisition of $1.9 million, consisting of $0.3 million in stock consideration, $1.3 million of promissory note, and $0.3 million in direct transaction costs, as acquired research and development expenses in the condensed consolidated statement of operations for the nine months ended September 30, 2025.

 

See Note 9, Notes Payable for additional information on the Note Payable.